Veracyte's approach to bladder cancer testing
EXCEPTIONAL TESTING FOR BLADDER CANCER
Better treatment planning with Decipher® Bladder Genomic Classifier
The Decipher Bladder Genomic Classifier helps physicians and their patients with bladder cancer navigate complex treatment decisions. The Decipher Bladder test uses whole-transcriptome analysis and machine-learning technology to classify bladder tumors into five molecular subtypes, each with distinct biological characteristics. Armed with this information, physicians may better guide bladder cancer treatment decisions for their patients.
Learn about Decipher for bladder cancer
Bladder Cancer: Statistics. Cancer.Net. Published March 2023. Accessed August 28, 2023. https://www.cancer.net/cancer-types/bladder-cancer/statistics
Bladder Cancer Prognosis and Survival Rates. National Cancer Institute. Published April 27, 2023. Accessed August 28, 2023. https://www.cancer.gov/types/bladder/survival
Bladder Cancer. Mayo Clinic. Published April 19, 2022. Accessed August 28, 2023. https://www.mayoclinic.org/diseases-conditions/bladder-cancer/diagnosis-treatment/drc-20356109
The Decipher Bladder Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.
This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.